Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

B cell lymphoma

Histone deacetylase (HDAC); proteasome

Cell culture and mouse studies suggest a combination of proteasome and HDAC inhibitors could help treat primary effusion lymphoma (PEL). In cultured PEL cells, a combination of the HDAC inhibitor Zolinza vorinostat and the proteasome inhibitor Velcade bortezomib decreased proliferation and increased apoptosis compared with either drug alone. In a mouse xenograft model for human PEL, the combination caused tumor regression and increased survival compared with either drug alone. Next steps could include evaluating the combination in a clinical trial.
Takeda Pharmaceutical Co. Ltd. and Johnson & Johnson market Velcade to treat multiple myeloma (MM) and mantle cell lymphoma (MCL).
Merck & Co. Inc. and Taiho Pharmaceutical Co. Ltd. market Zolinza to treat cutaneous T cell lymphoma (CTCL).

SciBX 6(20); doi:10.1038/scibx.2013.483
Published online May 23, 2013

Patent and licensing status unavailable

Bhatt, S. et al. J. Clin. Invest.; published online May 1, 2013;
doi:10.1172/JCI64503
Contact: Juan Carlos Ramos, University of Miami, Miami, Fla.
e-mail:
jramos2@med.miami.edu

Contact: Izidore S. Lossos, same affiliation as above
e-mail:
ilossos@med.miami.edu

Contact: Enrique A. Mesri, same affiliation as above
e-mail:
emesri@med.miami.edu